Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.77 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.77 |
| ▸ | BRD4 | O60885 | 5/20 | 0.67 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30910116 | 0.91 | HDAC1 (0.76) | HDAC1HDAC6BRD4KDM1AHDAC8 | |
| SCHEMBL26089401 | 0.91 | HDAC1 (0.76) | HDAC1HDAC6BRD4KDM1AHDAC8 | |
| SCHEMBL26933828 | 0.90 | HDAC1 (0.74) | HDAC1HDAC6BRD4KDM1ABCHE | |
| SCHEMBL31631234 | 0.90 | HDAC1 (0.74) | HDAC1HDAC6BRD4KDM1ABCHE | |
| SCHEMBL30673916 | 0.90 | HDAC1 (0.67) | HDAC1HDAC6BRD4KDM1ACYP2C9 | |
| SCHEMBL26092309 | 0.90 | HDAC1 (0.67) | HDAC1HDAC6BRD4KDM1ACYP2C9 | |
| SCHEMBL30910107 | 0.90 | HDAC1 (0.67) | HDAC1HDAC6BRD4KDM1ACYP2C9 | |
| SCHEMBL31631249 | 0.87 | HDAC1 (0.64) | HDAC1HDAC6BRD4KDM1ACYP2D6 | |
| SCHEMBL19278566 | 0.87 | HDAC1 (1.00) | HDAC1HDAC6BRD4KDM1ABCHE | |
| SCHEMBL5271480 | 0.87 | HDAC1 (0.61) | HDAC1HDAC6BRD4KDM1ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4700021-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Sapiensbio Inc. (KR) | 2026-02-25 | — | — | EP | disclosed |
| WO-2025127848-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 사피엔스바이오 | 2025-06-19 | — | — | WO | disclosed |
| EP-4538270-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | Sapiensbio Inc. (KR) | 2025-04-16 | — | — | EP | disclosed |
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | SAPIENSBIO INC. (KR) | 2025-01-02 | — | — | US | disclosed |
| EP-4421070-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Sapiensbio Inc. (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-118119612-A | Novel compounds and pharmaceutical compositions comprising the same | 萨皮恩斯生物有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023239227-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 사피엔스바이오 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239227-A1 | NOVEL COMPOUND, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 사피엔스바이오 | 2023-12-14 | — | — | WO | disclosed |
| WO-2023068755-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 사피엔스바이오 | 2023-04-27 | — | — | WO | disclosed |
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170224713-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | HCRTR1, NPSR1, NTSR1 | HDAC1 2754/4885HDAC6 3949/4885BRD4 1766/4885 |
| US-20250002464-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | RHOA, ACTR2, MFAP1 | HDAC1 1738/4885HDAC6 109/4885BRD4 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.